View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Apr. 15, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	Medicine Man Technologies, Inc.
Entity Central Index Key	0001622879
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Public Float			$ 34,919,284
Entity Common Stock, Shares Outstanding		27,953,848
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 321,788	$ 748,715
Accounts receivable	1,180,757	461,343
Accounts receivable - related party	125,112	25,719
Litigation receivable	1,281,511	0
Inventory	489,239	106,091
Other assets	50,824	42,819
Total current assets	3,449,231	1,384,687
Non-current assets
Fixed assets, net accumulated depreciation of $149,015 and $82,038	94,640	150,047
Intangible assets, net accumulated amortization of $13,903 and $7,388	81,197	87,712
Goodwill	12,304,306	9,304,306
Investment	2,199,344	0
Long-term note receivable, net of allowance	92,888	191,111
Other non-current assets	0	14,500
Total non-current assets	14,772,375	9,747,676
Total assets	18,221,606	11,132,363
Current liabilities
Accounts payable	202,515	123,251
Accounts payable - related party	71,312	155,177
Accrued expenses	291,084	0
Accrued taxes	582,931	0
Other liabilities	0	56,495
Total current liabilities	1,147,842	334,923
Long-term liabilities
Note payable - related party	0	58,280
Total long-term liabilities	0	58,280
Total liabilities	1,147,842	393,203
Shareholders' equity
Common stock $0.001 par value. 90,000,000 authorized, 27,753,310 and 22,991,137 were issued and outstanding December 31, 2018 and December 31, 2017, respectively.	27,875	23,113
Additional paid-in capital	20,239,163	13,997,441
Additional paid-in capital - Warrants	2,647,461	3,508,256
Retained earnings	(5,840,735)	(6,789,650)
Total Shareholders' equity	17,073,764	10,739,160
Total liabilities and stockholders' equity	$ 18,221,606	$ 11,132,363

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 149,015	$ 82,038
Accumulated amortization	$ 13,903	$ 7,388
Common stock authorized	90,000,000	90,000,000
Common stock par value	$ .001	$ .001
Common stock issued	27,753,310	22,991,137
Common stock outstanding	27,753,310	22,991,137

Consolidated Statement Of Comprehensive (Loss) And Income - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating revenues
Total revenue	$ 9,442,555	$ 3,529,584
Cost of goods and services
Cost of goods and services	2,306,871	1,033,678
Cost of goods and services - related party	270,639	268,603
Total cost of goods and services	2,577,510	1,302,281
Gross profit	6,865,045	2,227,303
Operating expenses
General and administrative	451,881	1,369,551
Professional services	885,149	543,314
Acquisition costs	0	150,261
Stock based compensation expenses	1,457,250	4,805,318
Officers and directors bonuses	265,871	150,392
Advertising	291,711	183,782
Conference and travel expenses	358,164	0
Salaries	984,678	260,635
Total operating expenses	4,694,704	7,463,253
Income from operations	2,170,341	(5,235,950)
Other income/expense
Interest Income	(30,001)	(30,001)
Net loss on derivative liability	0	14,459
Interest expense related to convertible notes	0	86,020
Loss (gain) on sales of assets	8,998	0
Loss on management fee contracts	0	70,257
Bad debt expense	196,112	0
Net loss on available for sale securities	0	4,706
Unrealized loss on investments	463,386	0
Other income	0	(219)
Total other expense	638,495	145,222
Net (loss) income before taxes	1,531,846	(5,381,172)
Income taxes
Income tax expense	582,931	0
Total income taxes	582,931	0
Net income (loss)	$ 948,915	$ (5,381,172)
Earnings per share attributable to common shareholders:
Basic (loss)/earnings per share	$ 0.04	$ (0.23)
Diluted (loss)/earnings per share	$ 0.03	$ (0.23)
Weighted average number of shares outstanding - Basic	25,121,896	22,991,137
Weighted average number of shares outstanding - Diluted	27,769,357	22,991,137
Comprehensive (loss) gain	$ 948,915	$ (5,381,172)
Product [Member]
Operating revenues
Total revenue	1,476,169	550,986
Product sales - related party [Member]
Operating revenues
Total revenue	555,434	532,222
Litigation revenue [Member]
Operating revenues
Total revenue	1,518,099	0
Cultivation Max [Member]
Operating revenues
Total revenue	21,218	0
Master Licensing Fees [Member]
Operating revenues
Total revenue	3,518,322	0
Licensing Fees [Member]
Operating revenues
Total revenue	751,414	1,425,806
Consulting Fees [Member]
Operating revenues
Total revenue	1,519,861	930,857
Reimbursements [Member]
Operating revenues
Total revenue	59,995	47,945
Services - related party [Member]
Operating revenues
Total revenue	16,423	0
Seminars and others [Member]
Operating revenues
Total revenue	$ 5,620	$ 41,768

Statement Of Changes In Stockholders' Equity - USD ($)	Common Stock	Additional Paid-In Capital	Unrealized loss on AFS	Accumulated Earnings (Loss)	Total
Beginning balance, shares at Dec. 31, 2016	10,402,500
Beginning balance, value at Dec. 31, 2016	$ 10,403	$ 1,026,052	$ (4,303)	$ (1,408,478)	$ (376,326)
Stock issued as compensation, shares	1,500,000
Stock issued as compensation, value	$ 1,500	2,539,499			2,540,999
Unrealized gain/(loss) on AFS			4,303		4,303
Stock issued for acquisitions, shares	9,255,544
Stock issued for acquisitions, value	$ 9,258	9,470,130			9,479,388
Warrants issued		2,100,318			2,100,318
Stock issued for convertible debt, shares	601,648
Stock issued for convertible debt, value	$ 718	787,220			787,938
Stock issued for cash, shares	1,041,912
Stock issued for cash, value	$ 1,044	465,226			466,270
Warrants issued for cash		928,828			928,828
Stock issued for services, shares	134,533
Stock issued for services, value	$ 135	163,865			164,000
Stock issued for cash (Related Party), shares	55,000
Stock issued for cash (Related Party), value	$ 55	24,559			24,614
Net income for the period				(5,381,172)	(5,381,172)
Ending balance, shares at Dec. 31, 2017	22,991,137
Ending balance, value at Dec. 31, 2017	$ 23,113	17,505,697	0	(6,789,650)	10,739,160
Stock issued for warrants exercised, shares	1,091,197
Stock issued for warrants exercised, value	$ 1,091	(1,091)
Stock issued as compensation, shares	800,000
Stock issued as compensation, value	$ 800	1,456,450			1,457,250
Stock issued for acquisitions, shares	1,933,329
Stock issued for acquisitions, value	$ 1,933	2,998,067			3,000,000
Adjustment for acquisition payment		(71,561)			(71,561)
Stock issued for cash, shares	937,647
Stock issued for cash, value	$ 938	999,062			1,000,000
Net income for the period				948,915	948,915
Ending balance, shares at Dec. 31, 2018	27,753,310
Ending balance, value at Dec. 31, 2018	$ 27,875	$ 22,886,624	$ 0	$ (5,840,735)	$ 17,073,764

Consolidated Statements Of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements Of Cash Flows - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net income (loss) for the period	$ 948,915	$ (5,381,172)
Adjustments to reconcile net income to net cash provided by operating activities
Loss (gain) on investment, net	463,386	14,458
Stock based compensation	1,457,250	4,805,318
Depreciation and amortization	81,960	63,737
Changes in operating assets and liabilities
Proceeds from note receivable	0	72,905
Accounts receivable	(2,100,318)	(462,062)
Inventory	(383,147)	(106,090)
Other assets	6,495	(15,839)
Accounts payable and other liabilities	812,919	334,748
Net cash earned (used) from operating activities	1,287,460	(673,997)
Cash flows from investing activities
Purchase of assets	(20,039)	(255,663)
Short term debt	(58,280)	0
Acquisition investment	(71,561)	217,458
AFS securities investment, net	0	4,303
Net cash used from investing activities	(149,880)	(33,902)
Cash flows from financing activities
Sale of common stock	1,000,000	1,185,755
Convertible debt	0	(80,665)
Net cash earned from financing activities	1,000,000	1,105,090
Net decrease in cash and cash equivalents	(426,927)	397,191
Cash and cash equivalents - beginning of period	748,715	351,524
Cash and cash equivalents - end of period	321,788	748,715
Non-Cash Transactions
Investment	(2,662,730)	0
Short Term Note Receivable	$ 98,223	$ 0

Organization and Nature of Operations

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Description

Organization and Nature of Operations:

Business Description – Business Activity: Medicine Man Technologies Inc. (the "Company") is a Nevada corporation incorporated on March 20, 2014. The Company is a cannabis consulting company providing services related to cost-efficient cannabis cultivation technologies focusing on quality as well as safety, retail operations related to the delivery of cannabis related products, and other related business lines as described in the Company’s operating strategic vision outlined below.

1. Liquidity and Capital Resources

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity and Capital Resources

1.	Liquidity and Capital Resources:

Cash Flows – During the fiscal year ended December 31, 2018 and 2017, the Company primarily used revenues from its operation supplemented by cash to fund its operations.

Cash and cash equivalents are carried at cost and represent cash on hand, deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date. The Company had $321,788 and $748,715 classified as cash and cash equivalents as of December 31, 2018, and December 31, 2017, respectively.

The Company has recently elected to accelerate its organic growth path through additional marketing, team development, synergistic acquisitions, and other corporate activities wherein it expects to generate negative cash flow and an additional demand for capital to fuel such growth.

The Company is commencing legal action against two clients for breach of contract, adding a significant value into its receivables for fees that had been booked due to forbearance grants by the Company that were subsequent violated, causing the Company to increase its receivables accordingly (see Part II, Item 1, Legal Proceedings).

2. Critical Accounting Policies and Estimates

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Critical Accounting Policies and Estimates

2.	Critical Accounting Policies and Estimates:

Basis of Presentation: These accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for annual financial statements.

Fair Value Measurements: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments include cash, accounts receivable, note receivable, accounts payables and tenant deposits. The carrying values of these financial instruments approximate their fair value due to their short maturities. The carrying amount of the Company’s debt approximates fair value because the interest rates on these instruments approximate the interest rate on debt with similar terms available to us. The Company’s derivative liability was adjusted to fair market value at the end of each reporting period, using Level 3 inputs.

The following is the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis at December 31, 2018 and December 31, 2017, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):

		December 31, 2018				December 31, 2017
Level 3 – Non-Marketable Securities – Non-recurring		$	2,199,344			$	–

Non-Marketable Securities at Fair Value on a Nonrecurring Basis — Certain assets are measured at fair value on a nonrecurring basis. The level 3 position consist of investments accounted for under the cost method. The Level 3 position consists of investments in equity securities held in private companies.

Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.

Accounts receivable: The Company extends unsecured credit to its customers in the ordinary course of business. Accounts receivable related to licensing, consulting and cultivation max revenues are recorded at the time the milestone is achieved resulting in the funds being due, services are delivered, and payment is reasonably assured. Licensing, consulting and cultivation max revenues are generally collected from 30 to 60 days after the invoice is sent. As of December 31, 2018, and December 31, 2017, the Company had accounts receivable of $2,587,380 and $487,062, respectively. The Company wrote off $0 of its accounts receivable in 2018. Due to the low volume of write offs, the Company uses the direct write off method versus having an allowance for uncollectible debts. The Company continues to accrue values for fees it would normally be earning during this quarter and as related to the ongoing legal action it initiated after the Client in question refused to pay fees due the Company in accordance with the Client acknowledged executed agreement. At December 31, 2018 the accounts receivable for this matter totals $1,281,511 and the revenue earned as of December 31, 2018 is $1,518,099. Further, the Company provided services to this Client for a period of thirteen months, agreeing conditionally to three modifications to forego certain revenue sharing payments in accordance with the agreement taking place in December of 2017, March of 2018, and May of 2018 which the Client subsequently violated. In July of this year the Company secured legal counsel in Clark County Nevada to pursue this Client's default of payments as legally due the Company. (See Part II, Item 1, Legal Proceedings).

Long term note receivable: In July 2016, the Company executed a non-binding Term Sheet to acquire Capital G Ltd, an Ohio limited liability company and its three wholly owned subsidiary companies, Funk Sac LLC, Commodogy LLC, and OdorNo LLC. The agreement was subject to the Company’s due diligence as well as execution of definitive agreements. In January 2017, the parties agreed not to proceed with this transaction. As part of the term sheet the Company agreed to loan Capital G the principal balance of $250,000 pursuant to the terms of a convertible note which accrues interest at the rate of 12% per annum and which became due November 1, 2017. As of September 30, 2018, this note has not been repaid when it became due. As of December 31, 2018, the Company has written off 100% or $250,000 of this balance plus accrued interest of $49,018. Due to this bad debt expense not being a part of the Company’s normal business this expense is categorized in other income and expense on the income statement. Management is currently in discussions on how to recover this loan. Additionally, as a part of the above-mentioned contract with CHV, the Company also provided CHV with a matching lending facility of $500,000 CAD in $125,000 CAD increments. As of 12.31.18, the Company has loaned CHV $125,000 CAD or $92,888. The Company had $92,888 and $191,111 classified as long-term note receivable as of December 31, 2018, and December 31, 2017, respectively.

Other assets (current and non-current): Other assets at December 31, 2018, and December 31, 2017 were $50,824 and $57,319, respectively including $29,005 in prepaid expenses and $21,819 in two security deposits.

Accounts payable: Accounts payable at December 31, 2018, and December 31, 2017 were $273,827 and $278,428, respectively and were comprised of operating accounts payable for various professional services incurred during the ordinary course of business.

Accrued expenses and other liabilities: Accrued expenses and other liabilities at December 31, 2018, and December 31, 2017 were $291,084 and $56,495, respectively. At December 31, 2018, this was comprised of $163,568 in customer deposits, $21,330 in deferred rent expense and $106,185 in accrued payroll.

Fair Value of Financial Instruments: The carrying amounts of cash and current assets and liabilities approximate fair value because of the short-term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. Available for sale securities are recorded at current market value as of the date of this report.

Revenue recognition and related allowances: Our revenue recognition policy is significant because the amount and timing of revenue is a key component of our results of operations. Certain criteria are required to be met in order to recognize revenue. If these criteria are not met, then the associated revenue is deferred until it is met. When consideration is received in advance of the delivery of goods or services, a contract liability is recorded. Our revenue contracts are identified when accepted from customers and represent a single performance obligation to sell our products to a customer.

The Company has five main revenue streams, product sales, licensing and consulting, cultivation max, reimbursements, investment and others.

Revenue from cultivation max, licensing and consulting services is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved.

Product Sales are recorded at the time that control of the products is transferred to customers. In evaluating the timing of the transfer of control of products to customers, we consider several indicators, including significant risks and rewards of products, our right to payment, and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to customers.

Revenue from seminar fees is related to one-day seminars and is recognized as earned at the completion of the seminar. The Company also recognizes expense reimbursement from clients as revenue for expenses incurred during certain jobs.

Intellectual Property Master Licensing Agreement with ABBA Medix Corp.

On July 17, 2018, Medicine Man Technologies, Inc. the “Company” entered into an intellectual property license agreement with Abba Medix Corp. (AMC), a wholly-owned subsidiary of publicly-traded Canada House Wellness Group, Inc. (CHV).

The license agreement granted AMC the right to use products and processes related to high-efficiency cultivation of cannabis, as well as various inventions, ideas, discoveries, algorithms, designs, hardware, prototypes, copyrights, processes, mask works, trade secrets, know-how, calculations, testing results, technical data, documentation, potential customer contracts, marketing ideas and other technology in the cannabis cultivation industry, in addition to all related trademarks, from the Company. The license was granted as of the effective date of the agreement for an 18-month period, and shall automatically renew for successive 18-month periods until the agreement is otherwise terminated.

As consideration for granting the license to AMC, the Company received the following:

$1,150,000 in cash;

$3,500,000 in shares of CHV common stock; and

Ongoing licensing fees calculated as a percentage of AMC’s sales revenue directly related to the Company’s intellectual property.

ASC 606 provides guidance in determining the proper accounting treatment for the license of the intellectual property requiring the Company had to complete a sequence of analyses. These analyses include the following: (i) sale versus licensing transactions; (ii) distinct performance obligations; (iii) the nature of the license; and (iv) the timing of recognition based on the nature of the license. Based on an analysis of ASC 606, the Company determined the following:

The license agreement establishes AMC’s right to use the intellectual property; it does not transfer any of the Company’s ownership in the assets. Therefore, the agreement is clearly identified as a licensing transaction.

The license agreement grants AMC the right to use the intellectual property immediately and does provide for the transfer of any other goods or services to AMC. The property is capable of being distinct, and the promise to transfer the property is distinct within the context of the contract. The Company recognized its license as distinct and a separate performance obligation.

The intellectual property is functional intellectual property as it has significant standalone functionality. The license agreement with AMC grants them with the exclusive right to use the Company’s intellectual property immediately upon the date of the agreement. This date clearly represents a transfer of control to the customer. Further upon its effectiveness, the Company established the right to payment and the customer accepted the asset. As control has been transferred to the customer, the Company has satisfied its performance obligation and, as such, is entitled to immediately recognize the $4,650,000 in revenue associated with the granting of the licensing rights.

Additionally, under the terms of the agreement, the Company agreed to provide a loan facility to AMC under the following terms:

“The Licensor (the Company) shall provide a lending facility to the Licensee (AMC) in $125,000 increments of up to $500,000; noting that any increment over the initial $250,000 advanced shall only be funded upon the Licensee’s funding of the second $575,000 amount to the Licensor. Such lending facilities shall bear a nominal interest rate and carry terms, to be agreed to by both parties. Both parties agree that each of the Licensor’s advances shall be first money in and first money to be repaid in accordance with the terms mutually agreed to.

The purpose of this lending facility was to provide financing support to AMC, the licensee of the Company’s intellectual property, for investing in capital expenses that would allow them to generate revenue that would result in a royalty being paid to Medicine Man Technologies, Inc. The Company is entitled to receive 4% of the gross revenues associated with the sale of Success Nutrients ® by AMC over the term of the agreement. The Company considered the guidance under ASC 606 in determining whether or not the facility had any impact on the Company’s ability to recognize revenue from the licensing agreement. Based upon the Company’s analysis, the Company determined the business purpose of the financing facility that it provided to AMC, was a separate agreement with distinct responsibilities from the Company’s performance obligations under the intellectual property license agreement. The Company considered the scope exceptions highlighted in 606-10-15-2(c) and determined that Topic 825, Financial Instruments more appropriately applied. The amount of revenue of $4,650,000 that the Company recognized, was not reduced by the amount of the $500,000 facility which the Company determined is a standalone contract with commercial substance and collectability. As of December 31, 2018, the Company recorded a trade accounts receivable on its balance sheet due from AMC of $250,000.

On July 31, 2018, the license agreement was amended solely to eliminate the equal $1,000,000 million-dollar stock swap element. Based upon the Company’s analysis of ASC 606-10-25-13, the Company determined the modification represented the elimination of a stock swap between the Company and its customer’s parent company, CHV. While the consideration had a defined value, the result of the modification does not beneficially or negatively impact either the Company or its customer. The Company determined that the remaining goods or services as of the time of the modification are not distinct and, form part of a single performance obligation that was partially, if not fully, satisfied. As the consideration represented an exchange of equal value between the two parties, the Company did not record any revenue adjustments (either as an increase or a reduction) due to the elimination of the stock swap.

Cultivation License Payment

On August 6, 2018, the Company entered into a license agreement with a client that was comprised of two basic elements:

Element One

The Company was hired to act as project management due to the Company’s industry knowledge to help a client prepare to cultivate their crop. The Company completed all of its work to get them growing by December 31, 2018. This element of the Company’s contract was simply charging an agreed upon fee for services performed. All fees were considered fully earned and were billed and collected in 2018.

Element Two

The second part of the license agreement called for the Company to receive a bonus equal to “25% of the value of the product grown over 2 pounds per light” for the next 5 years. “2 pounds per light” is a marijuana industry standard meaning that if the crop yield was above that standard, it would indicate that due to the Company’s expertise that the client crop was “above standard”. Under that clause, the Company would be sharing in the extra profit if it was achieved, because the expert advice provided by the Company would enable the client to generate a significant level of profit above industry standard. On December 14, 2018, the Company entered into an amendment to amend the terms of the August 6, 2018 license agreement:

The term for receiving 25% of the value grown over 2 pounds per light, was reduced from five years to three years

The 25% level was reduced to 5%

In return, the Company received a $1,000,000 fee which it billed in 2018 and collected in full in January 2019. Specifically, the wording in the addendum stated, “The aforementioned fee of $1,000,000 shall be deemed earned by the Licensor (Medicine Man) upon the execution of this Addendum and shall be payable before January 15, 2019”. The Company met all contractual terms prior to December 31, 2018 and have no ongoing contractual responsibility to provide consulting services in order to earn this fee. The client limited their exposure for potentially higher future payments by agreeing to a one-time payment of $1,000,000.

The amendment also provided that the client will reimburse the Company up to $11,000 a month for the cost of its employees if they are needed at the client’s locations. The Company considered this a pass thru item where no profit was recognized. Under the guidelines of ASC 606-10-25-27, an entity transfers control of a good or service over time and, therefore, satisfies a performance obligation and recognizes revenue over time, if one of the following criteria is met:

a. The customer simultaneously receives and consumes the benefits provided by the entity’s performance as the entity performs (see paragraphs 606-10-55-5 through 55-6).

b. The entity’s performance creates or enhances an asset (for example, work in process) that the customer controls as the asset is created or enhanced (see paragraph 606-10-55-7).

c. The entity’s performance does not create an asset with an alternative use to the entity (see paragraph 606-10-25-28), and the entity has an enforceable right to payment for performance completed to date (see paragraph 606-10-25-29).

As a result of the contractual consulting services the Company provided for Element One, control of the services has been transferred to the customer. These services enhanced The client’s crop output capabilities and clearly meet criteria (a) and (b) above, and, therefore were recorded as revenue in 2018.

With respect to Element Two in terms of considering revenue the method of recognition under 606, the following characteristics of the transaction were considered:

The Company had no further performance obligations

The customer contractually deemed this fee as earned

The future potential value of the reduction from 25% over five years, to 5% over three years, is an asset that legally passed to the client.

The customer paid the fee

Based on the analysis performed, the Company determined “control” at a point in time, transferred immediately to the client upon the signing of the amendment. As a result, the Company recorded a trade receivable of $1,000,000 on its balance sheet as of December 31, 2018, and $1,000,000 of revenue in its statement of operations for the year ended December 31, 2018. This $1,000,000 receivable was fully received in January of 2019.

The Company notes no change in our pattern of revenue recognition due to the adoption of FASB ASU 2014-09 “Revenue from Contracts with Customers (Topic 606)”. The Company believes that the revenue recognition related to our consulting, licensing and product sales are consistent with our current practice.

Costs of Goods and Services Sold – Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of Company’s products and services.

General & Administrative Expenses – General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services.

Advertising and Marketing Costs: Advertising and marketing costs are expensed as incurred were $291,711 and $183,782 during the twelve-month periods ended December 31, 2018 and 2017, respectively.

Stock based compensation: The Company accounts for share-based payments pursuant to ASC 718, “Stock Compensation” and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock and restricted stock awards using the Black-Scholes option pricing model.

Stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 and EITF 96-18 when stock or options are awarded for previous or current service without further recourse. The Company issued stock options to contractors and external companies that had been providing services to the Company upon their termination of services. Under ASC 718 and EITF 96-18 these options were recognized as expense in the period issued because they were given as a form of payment for services already rendered with no recourse.

Share based expense paid to through direct stock grants is expensed as occurred. Since the Company’s stock has become publicly traded, the value is determined based on the number of shares issued and the trading value of the stock on the date of the transaction. Prior to the Company’s stock being traded the Company used the most recent valuation. The Company recognized $1,457,250 in expenses for stock-based compensation to employees and consultants during the nine months ended December 31, 2018.

Income taxes: The Company has adopted SFAS No. 109 – “Accounting for Income Taxes”. ASC Topic 740 requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

Management fee contracts: In February 2017, the Company entered into a Merger Agreement with Pono Publications Ltd. (“Pono”), as well as a Share Exchange Agreement with Success Nutrients, Inc. (“SN”), each a Colorado corporation, in order to facilitate the acquisition of both of these entities. The ratification of the acquisition of these companies requires the approval of the holders of a majority of the Company’s shareholders, which was approved at the Company’s annual shareholder meeting held in May 2017. The relevant agreements provide that the effective date for accounting purposes would be April 1, 2017. Success Nutrients became a wholly owned subsidiary of Medicine Man Technologies, Inc. and the business conducted by Pono was incorporated into a newly formed wholly owned subsidiary, Medicine Man Consulting, Inc., which is also where the Company conducts its consulting service business.

In March 2017, the Company integrated Pono Publications and Success Nutrients into its operations including a lease for approximately 10,000 square feet of space located at 6660 East 47th Street, Denver, CO 80216. This integration also included four (4) full time team members as well as several independent contractors. From April 1, 2017 to September 30, 2017, the Company has agreed to manage the acquirees through a management fee agreement whereby all cash collected was recognized as other income and all cash expenses were direct costs of the project. As of September 30, 2017, the management contract resulted in cash collections of approximately $100,000 and cash expenditures of approximately $170,000 resulting in a net loss of $70,257 which was presented on a net basis as a loss in the other income portion of the Company’s income statement. As of April 1, 2017, the Company’s consolidated financial statements included these two entities.

3. Recent Accounting Pronouncements

12 Months Ended

Dec. 31, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recent Accounting Pronouncements

3.	Recent Accounting Pronouncements

FASB ASU 2016-02 “Leases (Topic 842)” – In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). ASU 2016-02 increases transparency and comparability among organizations by requiring lessees to record right-to-use assets and corresponding lease liabilities on the balance sheet and disclosing key information about lease arrangements. The new guidance will classify leases as either finance or operating (similar to current standard’s “capital” or “operating” classification), with classification affecting the pattern of income recognition in the statement of income. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company does expect the adoption of ASU 2016-02 to have an impact on our consolidated financial statements starting January 1, 2019.

FASB ASU 2016-15 “Statement of Cash Flows (Topic 230)” – In August 2016, the FASB issued 2016-15. Stakeholders indicated that there is a diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. Adoption of this ASU will not have a significant impact on our statement of cash flows.

FASB ASU 2017-01 “Clarifying the Definition of a Business (Topic 805)” – In January 2017, the FASB issued 2017-1. The new guidance that changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. The guidance requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities is not a business. The guidance also requires a business to include at least one substantive process and narrows the definition of outputs by more closely aligning it with how outputs are described in ASC 606. The ASU is effective for annual reporting periods beginning after December 15, 2017, and for interim periods within those years. Adoption of this ASU is not expected to have a significant impact on our consolidated results of operations, cash flows and financial position.

4. Stockholders' Equity

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Stockholders' Equity

4.	Stockholders’ Equity:

The Company’s initial authorized stock at inception was 1,000,000 Common Shares, par value $0.001 per share. In 2016 the Company subsequently amended its Articles of Incorporation to increase its authorized shares to 90,000,000 Common Shares, par value $0.001 per share and 10,000,000 Preferred Shares, par value $0.001 per share.

As of December 31, 2017, the Registrant had 22,991,137 shares of Common Stock issued and outstanding.

On July 9, 2018, the Company issued 625,000 shares of Common Stock under its 2017 Qualified Incentive Plan to various individuals in consideration of their services rendered in support of the Company.

On December 14, 2018, the Company issued 175,000 shares of Common Stock under its 2017 Qualified Incentive Plan to various individuals in consideration of their services rendered in support of the Company.

On or about March 31, 2018, the Company had $2,100,318 in issued warrants exercised for 1,091,197 shares of Common Stock, this was a cashless exercise.

On or about September 17, 2018, the Company issued 1,933,329 shares of its Common Stock as part of the consideration in acquiring Two JS LLC.

On or about June 1, 2018, the Company sold 937,647 shares of Common Stock to a private investor of the Company.

As of December 31, 2018, the Company had 27,753,310 Common Shares issued and outstanding.

5. Property and Equipment

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment

5.	Property and Equipment:

Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following:

	December 31, 2018			December 31, 2017
Furniture & Fixtures	$	98,395		$	107,945
Marketing Display		36,900			36,900
Vehicles		34,900			6,000
Office Equipment		74,361			81,240
	$	243,655		$	232,085
Less: Accumulated Depreciation		(149,015	)		(82,038	)
	$	94,640		$	150,047

Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates.

Furniture & Fixtures			3 years
Marketing Display			3 years
Vehicles			3 years
Office Equipment			3 years

Depreciation expense for the twelve-month periods ending December 31, 2018 and 2017 was $75,446 and $59,117 respectively.

6. Intangible Asset

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Asset

6.	Intangible Asset

On May 1, 2014, the Company entered into a non-exclusive Technology License Agreement with Futurevision, Inc., f/k/a Medicine Man Production Corporation, a Colorado corporation, dba Medicine Man Denver (“Medicine Man Denver”), a company owned and controlled by affiliates of the Company, whereby Medicine Man Denver granted a license to use all of their proprietary processes they have developed, implemented and practiced at its cannabis facilities relating to the commercial growth, cultivation, marketing and distribution of medical marijuana and recreational marijuana pursuant to relevant state laws and the right to use and to license such information, including trade secrets, skills and experience (present and future). As payment for the license rights the Company issued Medicine Man Denver (or its designees) 5,331,000 shares of the Company’s common stock. The Company accounted for this license in accordance with ASC 350-30-30 “Intangibles – Goodwill and Other by recognizing the fair value of the amount paid by the company for the asset at the time of purchase. Since the Company has a limited operating history, management determined to use par value as the value recognized for the transaction. Since the term of the initial license agreement is ten (10) years, the cost of the asset will be recognized on a straight-line basis over the life of the agreement. In addition, each period the Company will evaluate the intangible asset for impairment.

During 2017, the Company obtained two intangible assets, Product Agreement & Registration and a Trade Secret. These two intangible assets were acquired due to the result of the acquisition of Success and Pono on September 30, 2017. Refer to the Note 9 for further explanation of the purchase price accounting. The Company’s procurement of product registration during the year was within five states and Canada. The Company’s product was registered in California, Oregon, Colorado, Michigan, Arizona, Washington and all of Canada. The registration allows the Company to sell their product within the confines of that region. The registration fees capitalized are the initial costs to obtain the license. The licenses have nominal annual renewal costs. These subscriptions are amortized over a 15-year period.

During 2017, the Company incurred an intangible asset due to the development of the product’s nutrient recipe. The nutrient recipe development was a one-time fee, paid to the Company’s developer. The intellectual property is amortized over a 15-year economic life of the asset. The economic life of the asset is shorter than the indefinite life considered the legal life of the assets so 15 years is deemed the economic life of the asset.

During 2017, the Company attained one additional intangible asset, Product Agreement & Registration. The Company’s procurement of product registration during the year was within seven states. The Company’s product was registered in Florida, Illinois, Maine, Massachusetts, Minnesota, Nevada and Ohio. The registration allows the Company to sell their product within the confines of that region. The registration fees capitalized are the initial costs to obtain the license. The licenses have nominal annual renewal costs. These subscriptions are amortized over a 15-year period.

	December 31, 2018			December 31, 2017
License Agreement	$	5,300		$	5,300
Product License and Registration		57,300			57,300
Trade Secret - IP		32,500			32,500
	$	95,100		$	95,100
Less: Accumulated Amortization		(13,903	)		(7,388	)
	$	81,197		$	87,712

Amortization expense for the twelve-month periods ending December 31, 2018 and 2017 was $6,515 and $4,620, respectively.

7. Convertible Notes and Derivative Liability

12 Months Ended

Dec. 31, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Convertible Notes and Derivative Liability

7.	Convertible Notes and Derivative Liability:

In the year ended December 31, 2016 the Company raised $810,000 through a private placement of convertible promissory notes sold to certain accredited investors, bearing interest at 12%, with interest and principal due January 1, 2019. Upon issuance, each of the notes is immediately convertible at the noteholder’s election into the company’s common stock at $1.75 per share or 90% of the VWAP of the five days following the notice of conversion, whichever is lower. Since the conversion rate can be tied to an underlying item, convertible notes with warrants, are a derivative that is recorded as a liability at fair value and adjusted to fair value at the conclusion of each reporting period. The underlying assumptions used in the Black Scholes model to determine the fair value of the derivative liability were based on the individual date the notes were closed, volatility, the risk-free rate, the exercise price and the stock price at conversion.

During the last three months of 2017, all outstanding convertible note holders either converted their notes or the Company paid monies owed in full. The liability at December 31, 2018 is $0.

8. Related Party Transactions

12 Months Ended

Dec. 31, 2018

Related Party Transactions

8.	Related Party Transactions:

As of December 31, 2018, the Company had six related parties, Brett Roper, Future Vision dba Medicine Man Denver, Med Pharm Holdings, Med Pharm Iowa, De Best Inc. and Super Farm LLC. One of the Officers of the Company, Joshua Haupt, currently owns 20% of both De Best and Super Farm. Additionally, one of the Directors of the Company, Andy Williams, currently owns 38% of Future Vision dba Medicine Man Denver. Andy Williams also owns 10% of Med Pharm Holdings and 3% of Med Pharm Iowa. Brett Roper is the Chief Executive Officer of the Company.

As of December 31, 2018, the Company had net sales from Super Farm LLC totaling $264,103 and $88,063 in net sales from De Best Inc. The Company gives a larger discount on nutrient sales to related parties than non-related parties. As of December 31, 2018, the Company had accounts receivable balance with Super Farm LLC totaling $61,110 and $20,503 accounts receivable from De Best Inc. As of September 30, 2018, the company had an accounts payable balance to Brett Roper in the amount of $69,714.

As of December 31, 2018, the Company had sales from Future Vision dba Medicine Man Denver totaling $158,805, and an accounts receivable balance of $28,893. As of December 31, 2018, the Company had an accounts receivable balance owed from Future Vision totaling $2,986. As of December 31, 2018, the Company had sales from Med Pharm Iowa totaling $10,026 and $34,438 in sales from Med Pharm Holdings. The Company had an accounts receivable balance owed from Med Pharm Iowa totaling $1,195 and $10,425 owed from Med Pharm Holdings.

9. Goodwill and Acquisition Accounting

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Acquisition Accounting

9.	Goodwill and Acquisition Accounting:

On June 3, 2017, the Company issued an aggregate of 7,000,000 shares of its common stock for 100% ownership of both Success Nutrients and Pono Publications. The Company utilized purchase price accounting stating that net book value approximates fair market value of the assets acquired. The purchase price accounting resulted in $6,301,080 of Goodwill. The ASC at 350-20-35-3A directs that “An entity may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that the fair value of a reporting unit is less than its carrying amount, including goodwill. The Company had a valuation done at this time and the value exceeded the purchase price indicating that there would not be any impairment.

On July 21, 2017, the Company issued 2,258,065 shares of its Common Stock for 100% ownership of Denver Consulting Group (“DCG”). The Company utilized purchase price accounting stating that net book value approximates fair market value of the assets acquired. The purchase price accounting resulted in $3,003,226 of Goodwill. The ASC at 350-20-35-3A directs that “An entity may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that the fair value of a reporting unit is less than its carrying amount, including goodwill”. The Company obtained an independent valuation of the DCG on September 27, 2017. The fair market value on September 27, 2017 of DCG was $3,650,000, thus creating a fair market value greater than the carrying value of Goodwill. The ASC at 350-20-35-3D directs that “If an entity determines that it is not more likely that the fair value of a reporting unit is less than its carrying amount, then Goodwill impairment is unnecessary.” As of December 31, 2017, the Company determined that no impairment is necessary given the recent valuations and no change in qualitative factors.

On September 17, 2018, we closed the acquisition of Two JS LLC, dba The Big Tomato, a Colorado limited liability company. (“Big T” or “Big Tomato”). The Company issued an aggregate of 1,933,329 shares of its common stock for 100% ownership of Big Tomato. The Company utilized purchase price accounting stating that net book value approximates fair market value of the assets acquired. The purchase price accounting resulted in the Company valuing the investment as $3,000,000 of Goodwill. At September 17, 2018, the Company’s per share value of Common Stock was $1.55. There is no requirement for Big Tomato to have independent audited financial statement for the prior two fiscal years and any interim periods because the aggregate value of the acquisition is less than 20% of the Company’s current assets.

Big Tomato Balance Sheet

	Book/Fair Value			Book/Fair Value
*Assets*		*Liabilities*
Inventory	291,000	Accounts payable		272,266
Other assets	4,950	Customer Deposits		23,684
	295,950			295,950

*Purchase Price (1,933,3291.5517)**
		3,000,000
Less: BV of Assets		(295,950	)
Add: BV of Liabilities		295,950
Goodwill		3,000,000

As of December 31, 2018, the Company’s Goodwill has a balance of $12,304,306. This amount consisted of $3,003,226 from the DCG acquisition, $6,301,080 from the Pono and Success acquisition and $3,000,000 from the Big Tomato acquisition. As of December 31, 2018, the Company had an independent third-party valuation group perform an impairment analysis on our consolidated goodwill balance. It was noted that as of December 31, 2018, no impairment was needed.

10. Licensing agreement with Canada House Wellness Group Inc. (CSE: CHV):

12 Months Ended

Dec. 31, 2018

Licensing Agreement With Canada House Wellness Group Inc. Cse Chv

Licensing agreement with Canada House Wellness Group Inc. (CSE: CHV):

10.	Licensing agreement with Canada House Wellness Group Inc. (CSE: CHV):

On July 17, 2018, Medicine Man Technologies Inc. announced an exclusive licensing agreement with Canada House Wellness Group Inc. (CSE: CHV) (“Canada House”), through its wholly owned subsidiary Abba Medix Corp., for deployment of its intellectual property and product lines (Three a Light ®, Success Nutrients ®, General Intellectual Property) into the Canadian marketplace. The licensing agreement calls for an initial payment of $4.65M (CAD) in the form of cash and stock for licensing of Medicine Man Technologies intellectual property, product lines, and assignment of an existing Cultivation MAX agreement to Canada House. Medicine Man Technologies will also be entitled to revenue-based fees related to this deployment over the duration of the license agreement and will be assisting Canada House’s marketing efforts. This is a level 1 investment.

As of December 31, 2018, the Company recognized an unrealized loss on investment of $398,766 and initial revenue of $3,518,322 due to this transaction

11. Inventory

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventory

11.	Inventory:

As of December 31, 2018, and December 31, 2017, the Company had $489,239 and $106,091 of finished goods inventory, respectively. The Company only has finished goods within inventory because it does not produce any of its products. All inventory is produced by a third party. The inventory valuation method that the Company uses is the FIFO method. During 2018 and 2017, the Company had $0 obsolescence within its inventory.

12. Note Payable

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Note Payable

12.	Note Payable:

As of December 31, 2018, and December 31, 2017, the Company had a note payable balance of $0 and $58,280, respectively. The note payable is a balance that is due to an officer of the Company, Joshua Haupt. This note was fully repaid in the 1^st quarter of FY 2018.

13. Commitments and Concentrations

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Concentrations

13.	Commitments and Concentrations:

Office Lease (Medicine Man Technologies) – Denver, Colorado – The Company entered into a lease for office space at 4880 Havana Street, Suite 201, Denver, Colorado 80239. The lease period started March 1, 2017 and will terminate February 29, 2020, resulting in the following future commitments:

2019 fiscal year		$	171,000
2020 fiscal year			29,000

Office Lease (Big Tomato) – Denver, Colorado – The Company entered into a lease for office space at 695 Billings St, Suite A-F, Aurora, Colorado 80011. The lease period started July 1, 2017 and will terminate June 30, 2020, resulting in the following future commitments:

2019 fiscal year			77,808
2020 fiscal year			38,904

The Company notes that this lease is accelerated and the deferred rent expense at December 31, 2018 is $21,330. This amount is booked in “Accrued expenses” and is noted above in “Note 1.”

14. Warrants

12 Months Ended

Dec. 31, 2018

Warrants

Warrants

14.	Warrants:

During the period ended December 31, 2017, the Company issued 2,000,000 common stock purchase warrants to three employees of the Company with an exercise price of $1.445 per share for a period of time expiring on December 31, 2019. As of December 31, 2018, all of the warrants were exercised. Stock-based compensation expense recognized for warrants during the twelve-month period ended December 31, 2018 was $2,100,318.

During the period ended December 31, 2018, the Company issued 250,000 common stock purchase warrants to one employee of the Company with an exercise price of $1.49 per share for a period of time expiring on December 31, 2021. The Company accounts for its warrants issued in accordance with the US GAAP accounting guidance under ASC 480. We estimated the fair value of these warrants at the respective balance sheet dates using the Black-Scholes option pricing model as described in the stock-based compensation section above, based on the estimated market value of the underlying common stock at the valuation measurement date of $1.49, the remaining contractual term of the warrant of 3 years, risk-free interest rate of 2.48% and expected volatility of the price of the underlying common stock of 126%. There is a moderate degree of subjectivity involved when using option pricing models to estimate the warrants and the assumptions used in the Black Scholes option-pricing model are moderately judgmental.

During the period ended December 31, 2018, the Company issued 937,647 common stock purchase warrants under the private offering with an exercise price of $1.33 per share, expiring on March 17, 2019. As of December 31, 2018, none of the warrants were exercised. The stock purchase warrants have been accounted for as equity in accordance with FASB ASC 480, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, Distinguishing Liabilities from Equity.

During the quarter ended September 30, 2018, the Company issued zero common stock purchase warrants.

	Number of shares		Exercise Price
Balance as of December 31, 2017		3,500,566		–
Warrants issued		937,647	$	1.33
Warrants issued		209,248	$	1.49
Warrants exercised		2,000,000		–
Balance as of December 31, 2018		2,647,461

15. Tax Provision

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Tax Provision

15.	Tax Provision:

The Company utilizes FASB ASC 740, “Income Taxes” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established if it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company generated a deferred tax credit through net operating loss carry forwards. The Company had no tax provisions as of December 31, 2017 and December 31, 2016. The Company had a net loss during the year ended December 31, 2017 and the deferred tax asset has a full valuation against it.

The Company is registered in the State of Colorado and is subject to the United States of America tax law. As of December 31, 2018, the Company had incurred income on a tax basis resulting in the Company calculating that it owed $477,626 to the federal government at December 31, 2018 and $0 at December 31, 2017. In addition, the Company owed the State of Colorado $105,305 in 2018 and $0 at December 31, 2017.

16. Major Customers and Accounts Receivable

12 Months Ended

Dec. 31, 2018

Major Customers And Accounts Receivable

Major Customers and Accounts Receivable

16.	Major Customers and Accounts Receivable:

The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable. For the twelve months ended December 31, 2018, two customers accounted for 48% of revenue, one with 37% and another with 11%. For the twelve months ended December 31, 2018, three customers accounted for 88% of accounts receivable, one with 11%, one with 38% and another with 39%. The Company is currently pursuing litigation against two of these customers to receive contractual amounts owed. See “Part II, Item 1, Legal Proceedings” for further explanation.

17. Segment Information

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Segment Information

17.	Segment Information:

The Company has two identifiable segments as of December 31, 2018; licensing/consulting and products. The products segment sells merchandise directly to customers via e-commerce portals, through our proprietary websites and retail location. The licensing/consulting segment sales derives its revenue from licensing/consulting agreements with cannabis related entities. The following information represents segment activity for the twelve-month periods ended December 31, 2018 and 2017.

	For the twelve months ended
	December 31, 2018													December 31, 2017
	Products		License/Cons.			Cultivation Max		Master Licensing Fee		Other		Total		Products			License/Cons.			Other		Total
Revenues		2,031,603		2,271,275			1,539,317		3,518,322		82,038		9,442,555		1,083,208			2,356,663			89,713		3,529,584
Intangible assets amortization		5,987		528			–		–		–		6,515		4,090			530			–		4,620
Depreciation		5,848		69,598			–		–		–		75,446		4,320			54,797			–		59,117
Income (loss) from operations		878,067		(275,576	)		346,424		–		–		948,915		(71,561	)		(5,309,611	)		–		(5,381,172	)
Segment assets		5,361,127		12,860,478			–		–		–		18,221,605		566,681			10,820,260			–		11,386,941
Purchase of assets		32,500		–			–		–		–		32,500		27,594			–			–		27,594

18. Future Minimum Lease Payments

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Future Minimum Lease Payments

18.	Future Minimum Lease Payments:

The adoption of ASU 2016-02 will have a significant impact on our balance sheet as we will record material assets and obligations primarily related to our corporate office and equipment leases. We expect to record operating lease liabilities of approximately $375,000 based on the present value of the remaining minimum rental payments using discount rates as of the effective date. We expect to record corresponding right-of-use assets of approximately $350,000, based upon the operating lease liabilities adjusted for prepaid and deferred rent, unamortized initial direct costs, liabilities associated with lease termination costs and impairment of right-of-use assets recognized in retained earnings as of January 1, 2019. We do not expect a material impact on our statement of income or our statement of cash flows.

19. Earnings per share (Basic and Dilutive)

12 Months Ended

Dec. 31, 2018

Earnings per share attributable to common shareholders:

Earnings per share (Basic and Dilutive)

19.	Earnings per share (Basic and Dilutive):

In accordance with ASC Topic 280 – “Earnings per Share”, the basic earnings per common share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

The following is a reconciliation of the numerator and denominator used in the basic and diluted earnings per share ("EPS") calculations for the twelve months December 31, 2018 and 2017.

Numerator:
Net income (loss)	$	948,915	$	(5,381,172	)
Less: Gain in fair value of derivative liabilities, net of interest expense for convertible notes		–		(14,459	)
Adjusted net income (loss)	$	948,915	$	(5,395,631	)

Denominator:
Weighted-average shares of common stock		25,121,896		22,991,137
Dilutive effect of warrants		2,647,461		–
Diluted weighted-average of common stock		27,769,357		22,991,137

Net loss per common share from:
Basic		0.04		(0.23	)
Diluted		0.03		(0.23	)

20. Subsequent Events

12 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

Subsequent Events

20.	Subsequent events:

As of the filing date of this report, there are no material subsequent events.

2. Critical Accounting Policies and Estimates (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation

Fair Value Measurements

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

		December 31, 2018				December 31, 2017
Level 3 – Non-Marketable Securities – Non-recurring		$	2,199,344			$	–

Use of Estimates

Accounts receivable

Long term note receivable

Long term note receivable: In July 2016, the Company executed a non-binding Term Sheet to acquire Capital G Ltd, an Ohio limited liability company and its three wholly owned subsidiary companies, Funk Sac LLC, Commodogy LLC, and OdorNo LLC. The agreement was subject to the Company’s due diligence as well as execution of definitive agreements. In January 2017, the parties agreed not to proceed with this transaction. As part of the term sheet the Company agreed to loan Capital G the principal balance of $250,000 pursuant to the terms of a convertible note which accrues interest at the rate of 12% per annum and which became due November 1, 2017. As of September 30, 2018, this note has not been repaid when it became due. As of December 31, 2018, the Company has written off 100% or $250,000 of this balance plus accrued interest of $49,018. Management is currently in discussions on how to recover this loan. Additionally, as a part of the above-mentioned contract with CHV, the Company also provided CHV with a matching lending facility of $500,000 CAD in $125,000 CAD increments. As of 12.31.18, the Company has loaned CHV $125,000 CAD or $92,888. The Company had $92,888 and $191,111 classified as long-term note receivable as of December 31, 2018, and December 31, 2017, respectively.

Other assets (current and non-current)

Accounts payable

Accrued expenses and other liabilities

Fair Value of Financial Instruments

Revenue recognition and related allowances

The Company has five main revenue streams, product sales, licensing and consulting, cultivation max, reimbursements, investment and others.

Revenue from cultivation max, licensing and consulting services is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved.

Intellectual Property Master Licensing Agreement with ABBA Medix Corp.

Intellectual Property Master Licensing Agreement with ABBA Medix Corp.

As consideration for granting the license to AMC, the Company received the following:

$1,150,000 in cash;

$3,500,000 in shares of CHV common stock; and

Ongoing licensing fees calculated as a percentage of AMC’s sales revenue directly related to the Company’s intellectual property.

Additionally, under the terms of the agreement, the Company agreed to provide a loan facility to AMC under the following terms:

Cultivation License Payment

On August 6, 2018, the Company entered into a license agreement with a client that was comprised of two basic elements:

Element One

Element Two

The second part of the license agreement called for the Company to receive a bonus equal to “25% of the value of the product grown over 2 pounds per light” for the next 5 years. “2 pounds per light” is a marijuana industry standard meaning that if the crop yield was above that standard, it would indicate that due to the Company’s expertise that the the client crop was “above standard”. Under that clause, the Company would be sharing in the extra profit if it was achieved, because the expert advice provided by the Company would enable the client to generate a significant level of profit above industry standard. On December 14, 2018, the Company entered into an amendment to amend the terms of the August 6, 2018 license agreement:

The term for receiving 25% of the value grown over 2 pounds per light, was reduced from five years to three years

The 25% level was reduced to 5%

a. The customer simultaneously receives and consumes the benefits provided by the entity’s performance as the entity performs (see paragraphs 606-10-55-5 through 55-6).

b. The entity’s performance creates or enhances an asset (for example, work in process) that the customer controls as the asset is created or enhanced (see paragraph 606-10-55-7).

With respect to Element Two in terms of considering revenue the method of recognition under 606, the following characteristics of the transaction were considered:

The Company had no further performance obligations

The customer contractually deemed this fee as earned

The future potential value of the reduction from 25% over five years, to 5% over three years, is an asset that legally passed to the client.

The customer paid the fee

Costs of Goods and Services Sold

Costs of Goods and Services Sold – Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of Company’s products and services.

General and Administrative Expenses

General & Administrative Expenses – General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services.

Advertising and Marketing Costs

Advertising and Marketing Costs: Advertising and marketing costs are expensed as incurred were $291,711 and $183,782 during the twelve-month periods ended December 31, 2018 and 2017, respectively.

Stock-based compensation

Income taxes

Management fee contracts

2. Critical Accounting Policies and Estimates (Table)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of fair value measurement

		December 31, 2018				December 31, 2017
Level 3 – Non-Marketable Securities – Non-recurring		$	2,199,344			$	–

5. Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property and equipment table

Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following:

	December 31, 2018			December 31, 2017
Furniture & Fixtures	$	98,395		$	107,945
Marketing Display		36,900			36,900
Vehicles		34,900			6,000
Office Equipment		74,361			81,240
	$	243,655		$	232,085
Less: Accumulated Depreciation		(149,015	)		(82,038	)
	$	94,640		$	150,047

Schedule of property and equipment useful lives

Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates.

Furniture & Fixtures			3 years
Marketing Display			3 years
Vehicles			3 years
Office Equipment			3 years

6. Intangible Asset (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

License Agreement

	December 31, 2018			December 31, 2017
License Agreement	$	5,300		$	5,300
Product License and Registration		57,300			57,300
Trade Secret - IP		32,500			32,500
	$	95,100		$	95,100
Less: Accumulated Amortization		(13,903	)		(7,388	)
	$	81,197		$	87,712

9. Goodwill and Acquisition Accounting (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Acquisition information

Big Tomato Balance Sheet

	Book/Fair Value			Book/Fair Value
*Assets*		*Liabilities*
Inventory	291,000	Accounts payable		272,266
Other assets	4,950	Customer Deposits		23,684
	295,950			295,950

*Purchase Price (1,933,3291.5517)**
		3,000,000
Less: BV of Assets		(295,950	)
Add: BV of Liabilities		295,950
Goodwill		3,000,000

13. Commitments and Concentrations (Tables)

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of future operating lease obligation

2019 fiscal year		$	171,000
2020 fiscal year			29,000

2019 fiscal year			77,808
2020 fiscal year			38,904

14. Warrants (Tables)

12 Months Ended

Dec. 31, 2018

Warrants

Schedule of warrant activity

	Number of shares		Exercise Price
Balance as of December 31, 2017		3,500,566		–
Warrants issued		937,647	$	1.33
Warrants issued		209,248	$	1.49
Warrants exercised		2,000,000		–
Balance as of December 31, 2018		2,647,461

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

17. Segment Information (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

	For the twelve months ended
	December 31, 2018													December 31, 2017
	Products		License/Cons.			Cultivation Max		Master Licensing Fee		Other		Total		Products			License/Cons.			Other		Total
Revenues		2,031,603		2,271,275			1,539,317		3,518,322		82,038		9,442,555		1,083,208			2,356,663			89,713		3,529,584
Intangible assets amortization		5,987		528			–		–		–		6,515		4,090			530			–		4,620
Depreciation		5,848		69,598			–		–		–		75,446		4,320			54,797			–		59,117
Income (loss) from operations		878,067		(275,576	)		346,424		–		–		948,915		(71,561	)		(5,309,611	)		–		(5,381,172	)
Segment assets		5,361,127		12,860,478			–		–		–		18,221,605		566,681			10,820,260			–		11,386,941
Purchase of assets		32,500		–			–		–		–		32,500		27,594			–			–		27,594

19. Earnings per share (Basic and Dilutive) (Tables)

12 Months Ended

Dec. 31, 2018

Earnings per share attributable to common shareholders:

Basic and diluted earnings per share

Numerator:
Net income (loss)	$	948,915	$	(5,381,172	)
Less: Gain in fair value of derivative liabilities, net of interest expense for convertible notes		–		(14,459	)
Adjusted net income (loss)	$	948,915	$	(5,395,631	)

Denominator:
Weighted-average shares of common stock		25,121,896		22,991,137
Dilutive effect of warrants		2,647,461		–
Diluted weighted-average of common stock		27,769,357		22,991,137

Net loss per common share from:
Basic		0.04		(0.23	)
Diluted		0.03		(0.23	)

1. Liquidity and Capital Resources (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 321,788	$ 748,715	$ 351,524

2. Critical Accounting Policies and Estimates (Details - Nonrecurring fair value) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Fair Value Inputs Level 3 [Member] \| Fair Value Measurements Nonrecurring [Member]
Non-marketable securities	$ 2,199,344	$ 0

2. Critical Accounting Policies and Estimates (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2018	Dec. 31, 2017
Accounts receivable		$ 2,587,380	$ 487,062
Accounts receivable written off		0
Long term note receivable		92,888	191,111
Other assets		50,824	57,319
Accounts payable		273,827	278,428
Accrued expenses and other liabilities		291,084	56,495
Advertising and marketing expense		291,711	183,782
Stock based compensation expense		1,457,250	4,805,318
Loss on management fee contracts		0	$ 70,257
Capital G Ltd. [Member]
Short term note receivable, writen off		(250,000)
Canada House Wellness Group [Member]
Long term note receivable		92,888
AMC [Member]
Performance obligation revenue		4,650,000
AMC [Member] \| Trade Accounts Receivable [Member]
Accounts receivable		250,000
Pono Publications and Success Nutrients [Member]
Operating income	$ 100,000
Operating expenses	170,000
Loss on management fee contracts	$ 70,257
Prepaid Expenses [Member]
Other assets		29,005
Security Deposits [Member]
Other assets		21,819
Customer Deposits [Member]
Accrued expenses and other liabilities		163,568
Deferred Rent Expense [Member]
Accrued expenses and other liabilities		21,330
Accrued Payroll [Member]
Accrued expenses and other liabilities		$ 106,185

4. Stockholders' Equity (Details Narrative)	12 Months Ended
4. Stockholders' Equity (Details Narrative)	Dec. 31, 2018 USD ($) shares
Warrant exercises [Member]
Warrants exercised, stock issued	1,091,197
Warrants exercised, value \| $	$ 2,100,318
Two JS LLC [Member]
Stock issued for acquisitions, shares	1,933,329
Private Investor [Member] \| September 17, 2018 [Member]
Stock issued new, shares	937,647
2017 Qualified Incentive Plan [Member] \| Various Individuals [Member] \| July 9, 2018 [Member]
Stock issued for services, shares issued	625,000
2017 Qualified Incentive Plan [Member] \| Various Individuals [Member] \| December 14, 2018 [Member]
Stock issued for services, shares issued	175,000

5. Property and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property and Equipment, gross	$ 243,655	$ 232,085
Less: Accumulated Depreciation	(149,015)	(82,038)
Property and equipment, net	94,640	150,047
Furniture and Fixtures [Member]
Property and Equipment, gross	98,395	107,945
Marketing Display [Member]
Property and Equipment, gross	36,900	36,900
Vehicles [Member]
Property and Equipment, gross	34,900	6,000
Office Equipment [Member]
Property and Equipment, gross	$ 74,361	$ 81,240

5. Property and Equipment (Details - Expected life)	12 Months Ended
5. Property and Equipment (Details - Expected life)	Dec. 31, 2018
Furniture and Fixtures [Member]
Estimated useful life	3 years
Marketing Display [Member]
Estimated useful life	3 years
Vehicles [Member]
Estimated useful life	3 years
Office Equipment [Member]
Estimated useful life	3 years

5. Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
5. Property and Equipment (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 75,446	$ 59,117

6. Intangible Asset (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Intangible assets, gross	$ 95,100	$ 95,100
Less: accumulated amortization	(13,903)	(7,388)
Intangible assets, net	81,197	87,712
License Agreement [Member]
Intangible assets, gross	5,300	5,300
Product License and Registration [Member]
Intangible assets, gross	57,300	57,300
Trade Secret [Member]
Intangible assets, gross	$ 32,500	$ 32,500

6. Intangible Asset (Details Narrative) - USD ($)	12 Months Ended
6. Intangible Asset (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 6,515	$ 4,620

7. Convertible Notes and Derivative Liability (Details - Derivative liability)	Dec. 31, 2018 USD ($)
Debt Disclosure [Abstract]
Convertible note balance	$ 0

8. Related Party Transactions (Details Narrative)	12 Months Ended
8. Related Party Transactions (Details Narrative)	Dec. 31, 2018 USD ($)
Super Farm LLC [Member]
Revenue from related parties	$ 264,103
Accounts receivable from related parties	61,110
De Best [Member]
Revenue from related parties	88,063
Accounts receivable from related parties	20,503
Medicine Man Denver [Member]
Revenue from related parties	158,805
Accounts receivable from related parties	28,893
Med Pharm Iowa [Member]
Revenue from related parties	10,026
Accounts receivable from related parties	1,195
Med Pharm Holdings [Member]
Revenue from related parties	34,438
Accounts receivable from related parties	10,425
Future Vision [Member]
Accounts receivable from related parties	2,986
Brett Roper [Member]
Accounts payable to related party	$ 69,714

9. Goodwill and Acquisition Accounting (Details - Acquisition value) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Business Combination assumed assets/liabilities
Goodwill	$ 12,304,306	$ 9,304,306
Big Tomato [Member]
Business Combination assumed assets/liabilities
Inventory	291,000
Other assets	4,950
Total assets	295,950
Accounts payable	272,266
Customer deposits	23,684
Total liabilities	295,950
Purchase price	3,000,000
Less: Book value of assets	(295,950)
Add: Book value of liabilities	295,950
Goodwill	$ 3,000,000

9. Goodwill and Acquisition Accounting (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill	$ 12,304,306	$ 9,304,306
Impairment	0
Success Nutrients and Pono Publications [Member]
Goodwill	6,301,080	6,301,080
Impairment		$ 0
Stock issued for acquisition, shares		7,000,000
Denver Consulting Group [Member]
Goodwill	3,003,226	$ 3,003,226
Impairment		$ 0
Stock issued for acquisition, shares		2,258,065
Big Tomato [Member]
Goodwill	$ 3,000,000

10. Licensing agreement with Canada House Wellness Group Inc. (CSE: CHV) (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 9,442,555	$ 3,529,584
Licensing Agreement [Member] \| Canada House Wellness Group [Member]
Loss on investment	(398,766)
Master licensing fees [Member]
Revenues	$ 3,518,322

11. Inventory (Details Narrative) - USD ($)	12 Months Ended
11. Inventory (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished goods inventory	$ 489,239	$ 106,091
Inventory obsolescence	$ 0	$ 0

12. Note Payable (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Josh Haupt [Member]
Note payable	$ 0	$ 58,280

13. Commitments and Concentrations (Details)	Dec. 31, 2018 USD ($)
Office Lease [Member]
Future operating lease commitment, 2019	$ 171,000
Future operating lease commitment, 2020	29,000
Office and Warehouse Lease [Member]
Future operating lease commitment, 2019	77,808
Future operating lease commitment, 2020	$ 38,904

13. Commitments and Concentrations (Details Narrative)	Dec. 31, 2018 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Deferred rent expense	$ 21,330

14. Warrants (Details) - Warrants [Member]	12 Months Ended
14. Warrants (Details) - Warrants [Member]	Dec. 31, 2018 $ / shares shares
Warrants outstanding, beginning balance	3,500,566
Warrants issued	937,647
Warrants issued	209,248
Warrants exercised	2,000,000
Warrants outstanding, ending balance	2,647,461
Warrants issued Exercise Price \| $ / shares	$ 1.33
Warrants issued Exercise Price \| $ / shares	$ 1.49

14. Warrants (Details Narrative) - Warrants [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Private offering
Warrants issued	937,647
Warrant exercise price	$ 1.33
Warrant expiration date	Mar. 17, 2019
Warrants exercised	0
Three Employees [Member]
Warrants issued		2,000,000
Warrant exercise price		$ 1.445
Warrant expiration date		Dec. 31, 2019
Warrants exercised	2,000,000
Stock based compensation	$ 2,100,318
One Employee [Member]
Warrants issued	250,000
Warrant exercise price	$ 1.49
Warrant expiration date	Dec. 31, 2021

15. Tax Provision (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Internal Revenue Service (IRS) [Member]
Income tax liability	$ 477,626	$ 0
State of Colorado [Member]
Income tax liability	$ 105,305	$ 0

16. Major Customers and Accounts Receivable (Details Narrative) - One Customer [Member]	12 Months Ended
	Dec. 31, 2018
Sales Revenue, Net [Member]
Concentration percentage	37.00%
Sales Revenue, Net [Member]
Concentration percentage	11.00%
Accounts Receivable [Member]
Concentration percentage	11.00%
Accounts Receivable [Member]
Concentration percentage	38.00%
Accounts Receivable [Member]
Concentration percentage	39.00%

17. Segment Information (Details- Segment Information) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 9,442,555	$ 3,529,584
Depreciation	75,446	59,117
Income (loss) from operations	2,170,341	(5,235,950)
Products [Member]
Revenues	2,031,603	1,083,208
Intangible assets amortization	5,987	4,090
Depreciation	5,848	4,320
Income (loss) from operations	878,067	(71,561)
Segment assets	5,361,172	566,681
Purchase of assets	32,500	27,594
Licensing/Consulting [Member]
Revenues	2,271,275	2,356,663
Intangible assets amortization	528	530
Depreciation	69,598	54,797
Income (loss) from operations	(275,576)	(5,309,611)
Segment assets	12,860,478	10,820,260
Purchase of assets	0	0
Cultivation Max [Member]
Revenues	1,539,317
Income (loss) from operations	346,424
MasterLicensingFeeMember
Revenues	3,518,322
Other [Member]
Revenues	82,038	89,713
Licensing/Consulting and Products [Member]
Revenues	4,302,878	3,439,871
Intangible assets amortization	6,515	4,620
Depreciation	75,446	59,117
Income (loss) from operations	2,322,434	(5,381,172)
Segment assets	19,705,533	11,386,941
Purchase of assets	$ 32,500	$ 27,594

18. Future Minimum Lease Payments (Details Narrative)	Dec. 31, 2018 USD ($)
Notes to Financial Statements
Operating lease liabilities	$ 375,000
Operating lease right-of-use assets	$ 350,000

19. Earnings per share (Basic and Dilutive) (Details - Basic and diluted earnings per share ) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Numerator:
Net (loss) income	$ 948,915	$ (5,381,172)
Less: Gain in fair value of derivative liabilities, net of interest expense for convertible notes	0	(14,459)
Adjusted net income (loss)	$ 948,915	$ (5,395,631)
Denominator:
Weighted-average shares of common stock	25,121,896	22,991,137
Dilutive effect of warrants	2,647,461	0
Diluted weighted-average of common stock	27,769,357	22,991,137
Net loss per common share from Basic	$ 0.04	$ (0.23)
Net loss per common share from Diluted	$ 0.03	$ (0.23)